FDA Approves Expanded Indication for Anktiva in BCG-Unresponsive NMIBC
PharmaMar Joins OncoDaily Grand Rounds at ESMO 2026: Sarcoma Edition as Foundational Partner
Jazz EMERGE 402: Real-World Lurbinectedin Shows Clinically Meaningful Activity in Previously Treated SCLC
Ulrika Årehed Kågström: The Hidden Financial Burden of Cancer Beyond Treatment
FFCD-AC: 1L Chemotherapy for Metastatic Recurrence of Ampullary Adenocarcinoma
Men and Breast Cancer: More than just a support system
The Advocacy Lens - Breast Cancer Awareness Month Special
Giuseppe Curigliano Announces Milan as Host City for ESMO Congress 2028
OncoDaily GI is the dedicated GI cancer platform of OncoDaily, focused on the rapidly evolving field of gastrointestinal oncology. It covers the full spectrum of GI malignancies, including colorectal, anal canal, gastric, gastroesophageal junction (GEJ), esophageal, small bowel, pancreatic, hepatocellular, and biliary tract cancers. Through OncoDaily GI, readers can follow the latest clinical trial developments, ongoing research, FDA and EMA approvals, guideline updates, emerging therapies, advances in biomarkers and precision oncology, major conference findings, and interviews with leading experts in the field.
